Tuesday 17 September | |
JTC | Half Year Results |
Staffline | Half Year Results |
Personal Group | Half Year Results |
Smart Metering Systems | Half Year Results |
Uniphar | Half Year Results |
Aquis Exchange | Half Year Results |
Central Asia Metals | Half Year Results |
French Connection Group | Half Year Results |
Ocado Group | Q3 Results |
Wednesday 18 September | |
Kingfisher | Half Year Results |
Accesso Technology | Half Year Results |
Warpoint London | Half Year Results |
Pendragon | Half Year Results |
ClearStar | Half Year Results |
Maxcyte | Half Year Results |
Keywords Studios | Half Year Results |
Bonhill Group | Half Year Results |
Lloyd's of London | Half Year Results |
Surgical Innovations | Half Year Results |
Porvair | Trading Statement |
Pan African Resources | Full Year Results |
Thursday 19 September | |
Clinigen Group | Full Year Results |
Bluefields | Full Year Results |
Cambridge Cognition | Half Year Results |
Xeros Technology | Half Year Results |
hVIVO | Half Year Results |
City Pub Group | Half Year Results |
Next | Half Year Results |
Saga | Half Year Results |
Lamprell | Half Year Results |
Safestyle UK | Half Year Results |
Kier Group | Full Year Results |
IG Group | Q1 Results |
Sound Energy | Half Year Results |
Wilmington | Full Year Results |
Friday 20 September | |
Applegreen | Half Year Results |
Smiths Group | Full Year Results |
Hurricane Energy | Half Year Results |
Investec | Trading Statement |
Monday 23 September | |
Brady | Half Year Results |
Keystone Law | Half Year Results |
PureCircle | Full Year Results |
Faron Pharmaceuticals | Half Year Results |
Billington Holdings | Half Year Results |
Seeing Machines | Full Year Results |
ASA International | Half Year Results |
Oilex | Half Year Results |
Microsaic Systems | Half Year Results |
Instem | Half Year Results |
IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial
Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.
Read more